Skip to main content
  • Jon Serody, MD

    Serody Receives Grant to Evaluate Epigenetic Changes in Innate Immune Cells During Stem Cell Transplantation

    Jonathan Serody, MD, the Elizabeth Thomas Professor of Medicine, Microbiology and Immunology, and chief of the Division of Hematology, received an NIH (NHLBI) R01 grant of $3.4M to evaluate epigenetic changes in innate lymphoid cells as a mediator of acute Graft-Versus-Host Disease (GvHD) after stem cell transplantation. The grant is in collaboration with Samantha Pattenden, PhD, … Continued

  • Zeidner-Serody

    Immunotherapy After High-Dose Chemotherapy Leads to Favorable Outcomes in Acute Myeloid Leukemia

    A clinical trial conducted at UNC Lineberger Comprehensive Cancer Center and Johns Hopkins Sidney Kimmel Comprehensive Cancer Center found that high-dose cytarabine followed by subsequent immunotherapy treatment with pembrolizumab benefited patients with resistant or relapsed acute myeloid leukemia (AML), a highly aggressive cancer. The findings were published in Blood Cancer Dis … Continued

  • Shakira_Grant-1-200x300

    Grant Receives $200,000 to Study Impact of Multiple Myeloma on Older Adult Patients, Care Partners

    The National Institute on Aging has awarded Shakira Grant, MBBS, and the UNC Center for Aging and Health a 2-year, $200,000 grant to study the illness and treatment experiences and functional trajectories of older adults with multiple myeloma and their care partners. Grant is assistant professor in the divisions of hematology and geriatric medicine. Multiple myeloma is a disease … Continued

  • davis-phillips-josh-zeidner

    Emerging Therapies For AML With Myelodysplasia-Related Changes: Slowly But Surely Moving the Needle

    Patients with acute myeloid leukemia with myelodysplasia-related changes (AML-MRC) have historically poor outcomes with conventional chemotherapy regimens. Davis Phillips, MD, internal medicine resident, and Josh Zeidner, MD, associate professor of medicine in the division of hematology, published an article that reviews the data for existing therapeutic options for patients with … Continued

  • 21 SCD Conference vs 3

    Sickle Cell Disease Conference: Moving On – A Post COVID Look at Sickle Cell Disease, September 24-25, 2021

    The 9th Annual Sickle Cell Disease Conference encompasses two virtual sessions September 24 and 25, 2021, from 10 a.m. – 12 p.m. This conference is a joint activity between the UNC Sickle Cell Disease Program and Duke University School of Nursing. Session one on September 24 will provide an update on the latest evidence in sickle cell management, including new FDA-approved pharma … Continued

  • Joshua-zeidner

    Zeidner Explains Transformation to AML in Higher-Risk MDS On OncLive.

    Joshua F. Zeidner, MD, associate professor of medicine in the division of hematology, discussed the risk of transformation to acute myeloid leukemia (AML) in higher-risk myelodysplastic syndromes (HR-MDS), recently on OncLiveTV. Watch OncLive TV.  

  • Natalie Grover, MD

    Promising Therapy For Patients With Relapsed/Refractory Hodgkin Lymphoma

    Natalie Grover, MD, assistant professor in the division of hematology and clinical director of the cell therapy program in the Lineberger Comprehensive Cancer Center, discusses her research on anti-CD30 CAR-T therapy for patients with relapsed/refractory Hodgkin lymphoma in a new video featured on the Oncology Learning Network. Following is an excerpt from the transcript: “CAR-T … Continued

  • sickle-cell-clot

    Pawlinski, Key Awarded $2.8 Million Grant To Study VTE in Sickle Cell Disease

    Rafal Pawlinski, PhD, the Lenvil Lee Rothrock Distinguished Professor of Medicine, and Nigel Key, MD, the Harold R. Roberts Distinguished Professor, both professors in the department of medicine’s division of hematology and members of the UNC Blood Research Center, have been awarded a $2.8 million, 4-year R01 grant from the NIH-NHLBI to investigate the mechanism of venous thrombo … Continued

  • Raj Kasthuri, MD

    Kasthuri Leads Post-Hospital Thrombosis Prevention Study For Covid Patients

    UNC is now a fully active clinical site for the ACTIV-4c Post-Hospital Thrombosis Prevention Study. This protocol is part of the larger ACTIV (Accelerating COVID-Therapeutic Interventions and Vaccine) study. This protocol focuses on preventing blood clots in patients discharged after being hospitalized with COVID-19. UNC is now enrolling participants in this adaptive, prospective … Continued

  • Nigel S. Key, MB, ChB, FRCP

    Can AstraZeneca Dispel Doubts About Its Shots?

    The AstraZeneca shot was supposed to be the vaccine for a couple of billion people. But after reports the shot may trigger a rare side effect, public health officials worry that the people in some countries may have lost faith in the world’s most important vaccine. In an article published by MSN.com and National Geographic, Nigel Key, MD, the Harold R. Roberts Distinguished Profe … Continued